Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1344
{ "count": 24333, "next": "http://api.gregory-ms.com/articles/?format=api&page=1345", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1343", "results": [ { "article_id": 439535, "title": "Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review", "summary": "<jats:p> Context There is an emerging body of literature regarding multiple sclerosis (MS) in African-Americans (AA) that suggests more rapid progression and a worse prognosis in this group. A phenotype of opticospinal MS has been proposed by some publications. </jats:p><jats:p> Objective To determine whether AA with MS have a different clinical phenotype, different distribution of clinical subtypes, and/or different levels of disability than Caucasians (CA) with MS. Specifically, is the disability attributable to severe cerebellar disease, which limits ambulation and function? Design: Retrospective chart analyses of a patient cohort from an academic MS center. </jats:p><jats:p> Patients A total of 86 AA were identified with MS, 79 were followed for ≥5 years. The control group consisted of 80 randomly-selected CA with MS and similar follow-up. </jats:p><jats:p> Outcome measures EDSS at diagnosis, five-year follow-up, and last follow-up; time to walking assistance device; disease subtype; involved functional systems. </jats:p><jats:p> Results AA MS patients displayed more cerebellar dysfunction, and worse EDSS scores at diagnosis, at four to six years follow-up from diagnosis, and at last follow-up compared to the CA MS patients with similar length of follow-up. AA MS patients had earlier and more frequent gait difficulty requiring use of a cane or wheelchair. AA MS patients had a higher prevalence of primary progressive (PP) MS (22 versus 9%) and a lower rate of relapsing-remitting (RR) MS (30 versus 52%) compared to CA. </jats:p><jats:p> Conclusions Compared to CA patients, MS in AA is characterized by a higher incidence of cerebellar dysfunction and a more rapid accumulation of disabilities. In this cohort, AA patients had a relatively higher rate of the PPMS subtype. These data suggest the presence of fundamental differences in the clinical phenotype and the natural history of MS in AA. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070923", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 274736, "given_name": "R T", "family_name": "Naismith", "ORCID": null, "country": null }, { "author_id": 274738, "given_name": "K", "family_name": "Trinkaus", "ORCID": null, "country": null }, { "author_id": 274740, "given_name": "A H", "family_name": "Cross", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.260993Z", "noun_phrases": [ "African-Americans", "multiple sclerosis" ], "doi": "10.1177/1352458506070923", "access": "restricted", "takeaways": " There is an emerging body of literature regarding MS in African-Americans (AA) that suggests more rapid progression and a worse prognosis in this group . AA MS patients displayed more cerebellar dysfunction, and worse EDSS scores at diagnosis, at four to six years follow-up from diagnosis, and at last follow-ups compared to the CA MS patients . AA patients had a relatively higher rate of the PPMS subtype .", "categories": [] }, { "article_id": 439534, "title": "Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years", "summary": "<jats:p> TNF-α, IL-12p35, IL-12p40, IL-4, IL-10, TGF-β1, CCR3, CXCR3, CCR5, Fas and FasL mRNA levels in PBMC of 25 multiple sclerosis (MS) patients were quantified at baseline by real-time PCR according to a post-hoc study design. The baseline values of the different markers were analysed with respect to their correlation with the increase in disability over a period of 10 years. High levels of Fas mRNA were associated with a favourable disease course in relapsing-remitting (RR) MS (R<jats:sup>2</jats:sup> = 0.74, P = 0.0001, n = 13), as measured by the Expanded Disability Status Scale (EDSS); high levels of FasL mRNA were associated with relatively mild disease progression (R<jats:sup>2</jats:sup> = 0.86, P = 0.0001, n = 12) in secondary progressive (SP) MS. These findings suggest that Fas-mediated apoptosis plays a major role in the mechanism underlying long-term disease progression in MS. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070826", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 311481, "given_name": "L", "family_name": "Lopatinskaya", "ORCID": null, "country": null }, { "author_id": 311482, "given_name": "J", "family_name": "Zwemmer", "ORCID": null, "country": null }, { "author_id": 292735, "given_name": "B", "family_name": "Uitdehaag", "ORCID": null, "country": null }, { "author_id": 311483, "given_name": "K", "family_name": "Lucas", "ORCID": null, "country": null }, { "author_id": 270070, "given_name": "C", "family_name": "Polman", "ORCID": null, "country": null }, { "author_id": 311484, "given_name": "L", "family_name": "Nagelkerken", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.259999Z", "noun_phrases": [ "Mediators", "apoptosis Fas", "FasL", "disability progression", " multiple sclerosis", "a period", "10 years" ], "doi": "10.1177/1352458506070826", "access": "restricted", "takeaways": " Fas and FasL mRNA levels in PBMC of 25 MS patients were quantified at baseline by real-time PCR according to a post-hoc study design . The baseline values of the different markers were analysed with respect to their correlation with the increase in disability over a period of 10 years . High levels of Fas mRNA were associated", "categories": [] }, { "article_id": 439533, "title": "Correlation of magnetization transfer and diffusion magnetic resonance imaging in multiple sclerosis", "summary": "<jats:p> The aim of this study was to correlate diffusion to magnetization transfer (MT) magnetic resonance imaging (MRI) results in multiple sclerosis (MS), in order to establish if the former technique provides complementary information. Magnetization transfer ratio (MTR) and apparent diffusion coefficient (ADC) were measured in 156 different regions of interest (ROIs) of 14 MS patients, where 84 corresponded to T1 hypointense lesions, 60 to T1 isointense lesions and 12 to regions of normal appearing white matter (NAWM). MTR mean value was higher for T1 isointense than for T1 hypointense lesions, and lower when compared to NAWM. ADC mean value for T1 isointense lesions was higher than for NAWM, but lower than for T1 hypointense lesions. A significant negative correlation was found between ADC and MTR for hypointense lesions (Pearson’s r =- 0.758, PB < 0.001), whereas this correlation was much weaker for T1 isointense lesions (Pearson’s r =- 0.256, P = 0.049). There was no correlation between ADC and MTR for NAWM. The fact that ADC and MTR show a strong correlation only for T1 hypointense lesions indicates that, when tissue integrity is not severely compromised, as in the case of T1 isointense lesions or NAWM, ADC and MTR might be sensitive to different pathological processes. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070824", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 289989, "given_name": "M CG", "family_name": "Otaduy", "ORCID": null, "country": null }, { "author_id": 252696, "given_name": "D", "family_name": "Callegaro", "ORCID": null, "country": null }, { "author_id": 289990, "given_name": "L A", "family_name": "Bacheschi", "ORCID": null, "country": null }, { "author_id": 289991, "given_name": "C C", "family_name": "Leite", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.259140Z", "noun_phrases": [ "Correlation", "magnetization transfer", "diffusion magnetic resonance imaging", "multiple sclerosis" ], "doi": "10.1177/1352458506070824", "access": "restricted", "takeaways": " Magnetization transfer ratio (MTR) and apparent diffusion coefficient (ADC) were measured in 156 different regions of interest (ROIs) of 14 MS patients . MTR mean value was higher for T1 isointense lesions than T1 hypointense lesions and lower for regions of normal appearing white matter (NAWM)", "categories": [] }, { "article_id": 439532, "title": "MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis", "summary": "<jats:p> Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized in local and regional outcome studies in multiple sclerosis (MS) and has yielded invaluable epidemiological information. The World Wide Web now provides an excellent opportunity for an international, collaborative cohort study of MS outcomes. A web platform-MSBase-has been designed to collect prospective data on patients with MS. It is purely observational, enabling participating neurologists to contribute data on diagnosis, treatment and progress, to review anonymous aggregate data and to benchmark their patient population against other patient subsets or the entire dataset. MSBase facilitates collaborative research by allowing the online creation of investigator-initiated regional, national and international substudies. The registry aims to answer epidemiological questions that can only be addressed by prospective assessments of large patient cohorts. The registry is funded through the independent MSBase Foundation, and governed by an International Scientific Advisory Board. The MSBase Foundation commenced operations in July 2004 and since then, 22 neurologists from 11 countries have joined MSBase and are contributing 2400 patients to the total data pool. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070775", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 281525, "given_name": "H", "family_name": "Butzkueven", "ORCID": null, "country": null }, { "author_id": 279872, "given_name": "J", "family_name": "Chapman", "ORCID": null, "country": null }, { "author_id": 284279, "given_name": "E", "family_name": "Cristiano", "ORCID": null, "country": null }, { "author_id": 292619, "given_name": "F", "family_name": "Grand’Maison", "ORCID": null, "country": null }, { "author_id": 292620, "given_name": "M", "family_name": "Hoffmann", "ORCID": null, "country": null }, { "author_id": 282593, "given_name": "G", "family_name": "Izquierdo", "ORCID": null, "country": null }, { "author_id": 292621, "given_name": "D", "family_name": "Jolley", "ORCID": null, "country": null }, { "author_id": 242102, "given_name": "L", "family_name": "Kappos", "ORCID": null, "country": null }, { "author_id": 250329, "given_name": "T", "family_name": "Leist", "ORCID": null, "country": null }, { "author_id": 292623, "given_name": "D", "family_name": "Pöhlau", "ORCID": null, "country": null }, { "author_id": 292624, "given_name": "V", "family_name": "Rivera", "ORCID": null, "country": null }, { "author_id": 241600, "given_name": "M", "family_name": "Trojano", "ORCID": null, "country": null }, { "author_id": 292625, "given_name": "F", "family_name": "Verheul", "ORCID": null, "country": null }, { "author_id": 292626, "given_name": "J-P", "family_name": "Malkowski", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.258305Z", "noun_phrases": [ "an international, online registry", "platform", "multiple sclerosis" ], "doi": "10.1177/1352458506070775", "access": "restricted", "takeaways": " A web platform-MSBase-has been designed to collect prospective data on patients with MS . 22 neurologists from 11 countries have joined MSBase and are contributing 2400 patients to the total data pool . The registry aims to answer epidemiological questions that can only be addressed by prospective assessments of large patient cohorts .", "categories": [] }, { "article_id": 439531, "title": "Multiple sclerosis-associated retrovirus in early multiple sclerosis: a six-year follow-up of a Sardinian cohort", "summary": "<jats:p> The human endogenous retroviruses (HERV)-W family contains an extracellular particle detected in multiple sclerosis (MS) patients and designated as MS-associated retrovirus (MSRV). Through nested RT-PCR assays specific for pol MSRV gene, we preliminary reported that its presence in the cerebrospinal fluid (CSF) of early MS patients could be indicative of a poor prognosis upon a three-year follow-up. In the present clinical study, we enlarged our blind observation up to six years. At study entry, 10 MS patients were MSRV<jats:sup>-</jats:sup> and eight were MSRV<jats:sup>+</jats:sup> in the CSF, both groups having a similar mean age and Expanded Disability Status Scale (EDSS) score. After six year follow-up, the mean EDSS significantly differed between the MSRV<jats:sup>-</jats:sup> and MSRV<jats:sup>+</jats:sup> cohorts (4.3 versus 2.2; P = 0.004), as did the annual relapse rate (0.5 in the MSRV<jats:sup>-</jats:sup> versus 0.3 in the MSRV<jats:sup>+</jats:sup>; P = 0.01). Finally, two MSRV<jats:sup>-</jats:sup> patients entered the progressive phase, whilst none of the MSRV<jats:sup>+</jats:sup> group entered this phase, and 9/10 MSRV<jats:sup>-</jats:sup> versus 2/8 MSRV<jats:sup>+</jats:sup> patients were treated with immunomodulatory or immunosuppressive drugs (P = 0.009). In conclusion, we found that the presence of MSRV virions in the CSF at the onset of MS is associated, not only with disability accumulation, but also with a higher rate of clinical re-exacerbations. With the known potential pathogenic effects of MSRV given in the literature, further investigations on MSRV are warranted. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070773", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 280630, "given_name": "S", "family_name": "Sotgiu", "ORCID": null, "country": null }, { "author_id": 280633, "given_name": "G", "family_name": "Arru", "ORCID": null, "country": null }, { "author_id": 280634, "given_name": "G", "family_name": "Mameli", "ORCID": null, "country": null }, { "author_id": 280635, "given_name": "C", "family_name": "Serra", "ORCID": null, "country": null }, { "author_id": 255003, "given_name": "M", "family_name": "Pugliatti", "ORCID": null, "country": null }, { "author_id": 280636, "given_name": "G", "family_name": "Rosati", "ORCID": null, "country": null }, { "author_id": 280637, "given_name": "A", "family_name": "Dolei", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.257442Z", "noun_phrases": [ "Multiple sclerosis-associated retrovirus", "early multiple sclerosis", "a six-year follow-up", "a Sardinian cohort" ], "doi": "10.1177/1352458506070773", "access": "restricted", "takeaways": " The human endogenous retroviruses (HERV)-W family contains an extracellular particle detected in multiple sclerosis patients and designated as MS-associated retrovirus (MSRV) The presence of MSRV virions in the CSF at the onset of MS is associated, not only with disability accumulation, but also with a higher rate of clinical re-exacerbations .", "categories": [] }, { "article_id": 439530, "title": "The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis", "summary": "<jats:p> Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral leukoplakia and the inflammatory disease, ulcerative colitis. We hypothesized that BBI may modulate experimental autoimmune encephalomyelitis (EAE), an animal model of MS. The BBI concentrate (BBIC), a soybean extract enriched in BBI, was administered to myelin basic protein (MBP)-immunized Lewis rats by gastric gavage in different treatment regimens, during the induction or the effector phase of disease. BBIC significantly delayed disease onset and suppressed disease severity, clinically and pathologically, in all treatment protocols. Both in vitro and ex vivo, BBIC inhibited MBP-specific proliferation of lymph node cells. BBIC reduced the activity of matrix metalloproteinase (MMP)-2 and -9 in spleen cell supernatants and was detected in the CNS of treated rats. BBIC suppresses EAE, it can be administered orally, and it is safe and relatively inexpensive. It may have a therapeutic role in patients with MS. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070769", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 252498, "given_name": "B", "family_name": "Gran", "ORCID": null, "country": null }, { "author_id": 297321, "given_name": "N", "family_name": "Tabibzadeh", "ORCID": null, "country": null }, { "author_id": 297322, "given_name": "A", "family_name": "Martin", "ORCID": null, "country": null }, { "author_id": 297323, "given_name": "E S", "family_name": "Ventura", "ORCID": null, "country": null }, { "author_id": 297324, "given_name": "J H", "family_name": "Ware", "ORCID": null, "country": null }, { "author_id": 297325, "given_name": "G-X", "family_name": "Zhang", "ORCID": null, "country": null }, { "author_id": 297326, "given_name": "J L", "family_name": "Parr", "ORCID": null, "country": null }, { "author_id": 297327, "given_name": "A R", "family_name": "Kennedy", "ORCID": null, "country": null }, { "author_id": 258073, "given_name": "A M", "family_name": "Rostami", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.256584Z", "noun_phrases": [ "The protease inhibitor", "Bowman-Birk Inhibitor", "suppresses", "experimental autoimmune encephalomyelitis", "a potential oral therapy", "multiple sclerosis" ], "doi": "10.1177/1352458506070769", "access": "restricted", "takeaways": " Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects . Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system . The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions .", "categories": [] }, { "article_id": 439529, "title": "Long-term emotional state of multiple sclerosis patients treated with interferon beta", "summary": "<jats:p> Objective: To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNβ) for at least four years. </jats:p><jats:p> Methods: Patients who had started IFNβ therapy prior to 2000 with a baseline psychological assessment were identified and scheduled for long-term emotional assessment with the following questionnaires-the Hamilton Depression Rating Scale, the Beck Depression Inventory and the State-Trait Anxiety Inventory. </jats:p><jats:p> Results: A total of 262 patients started IFNβ therapy in our MS clinic within the period 1995-1999. Baseline emotional assessment was available from 246 MS patients. Long-term assessment was conducted on 234 patients. After a mean follow-up of 65 months (43-98), 52 patients (22.3%) had withdrawn from IFNβ therapy. The comparisons, obtained from baseline and follow-up scores, showed an improvement in the depressive and anxiety symptoms of patients who adhered to IFNβ treatment. Logistic regression analysis indicated that an increase in physical disability and the presence of depressive symptoms at baseline were best predictors for long-term depressive symptoms. </jats:p><jats:p> Conclusions: The present results support the absence of emotional worsening in MS patients treated with IFNβ for a long period of time. Increased disability and the presence of baseline depressive symptoms predicted the presence of depressive symptoms at follow-up. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506070748", "published_date": "2006-11-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 333021, "given_name": "J", "family_name": "Porcel", "ORCID": null, "country": null }, { "author_id": 255590, "given_name": "J", "family_name": "Río", "ORCID": null, "country": null }, { "author_id": 333022, "given_name": "A", "family_name": "Sánchez-Betancourt", "ORCID": null, "country": null }, { "author_id": 333023, "given_name": "M J", "family_name": "Arévalo", "ORCID": null, "country": null }, { "author_id": 255585, "given_name": "M", "family_name": "Tintoré", "ORCID": null, "country": null }, { "author_id": 255592, "given_name": "N", "family_name": "Téllez", "ORCID": null, "country": null }, { "author_id": 333024, "given_name": "C", "family_name": "Borràs", "ORCID": null, "country": null }, { "author_id": 255589, "given_name": "C", "family_name": "Nos", "ORCID": null, "country": null }, { "author_id": 271470, "given_name": "X", "family_name": "Montalbán", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.255559Z", "noun_phrases": [ "Long-term emotional state", "multiple sclerosis patients", " interferon beta" ], "doi": "10.1177/1352458506070748", "access": "restricted", "takeaways": " A total of 262 patients started IFNβ therapy in our MS clinic within the period 1995-1999 . Logistic regression analysis indicated that an increase in physical disability and the presence of depressive symptoms at baseline were best predictors for long-term depressive symptoms . After a mean follow-up of 65 months (43-98), 52 patients (22.3%) had withdrawn from therapy .", "categories": [] }, { "article_id": 439528, "title": "Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations", "summary": "<jats:p> Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis (MS). Four immunopathological patterns (IP) have been recognized in early active MS lesions, suggesting heterogeneous pathogenic mechanisms. Whether MOG antibodies contribute to this pathological heterogeneity and potentially serve as biomarkers to identify specific pathological patterns is unknown. Here we report the frequencies of antibodies to human recombinant MOG (identified by Western blot and enzymelinked immunoabsorbent assay (ELISA)) in patients with pathologically proven demyelinating disease, and investigate whether antibody status is associated with clinical course, HLA-DR2 genotype, IP or treatment response to plasmapheresis. The biopsy cohort consisted of 72 patients: 12 pattern I, 43 pattern II and 17 pattern III. No association was found between MOG antibody status and conversion to clinically definite MS, DR-2 status, IP or response to plasmapheresis. There was poor agreement between Western blot and ELISA (kappa=0.07 for MOG IgM). Fluctuations in antibody seropositivity were seen for 3/4 patients tested serially by Western blot. This study does not support a pathologic pattern-specific role for MOG-antibodies. Variable MOG-antibody status on serial measurements, coupled with the lack of Western blot and ELISA correlations, raises concern regarding the use of MOG-antibody as an MS biomarker and underscores the need for methodological consensus. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506072189", "published_date": "2007-01-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 255264, "given_name": "S J", "family_name": "Pittock", "ORCID": null, "country": null }, { "author_id": 255265, "given_name": "M", "family_name": "Reindl", "ORCID": null, "country": null }, { "author_id": 255266, "given_name": "S", "family_name": "Achenbach", "ORCID": null, "country": null }, { "author_id": 255267, "given_name": "T", "family_name": "Berger", "ORCID": null, "country": null }, { "author_id": 255268, "given_name": "W", "family_name": "Bruck", "ORCID": null, "country": null }, { "author_id": 255269, "given_name": "F", "family_name": "Konig", "ORCID": null, "country": null }, { "author_id": 255270, "given_name": "Y", "family_name": "Morales", "ORCID": null, "country": null }, { "author_id": 255271, "given_name": "H", "family_name": "Lassmann", "ORCID": null, "country": null }, { "author_id": 255272, "given_name": "S", "family_name": "Bryant", "ORCID": null, "country": null }, { "author_id": 255273, "given_name": "S B", "family_name": "Moore", "ORCID": null, "country": null }, { "author_id": 255274, "given_name": "B M", "family_name": "Keegan", "ORCID": null, "country": null }, { "author_id": 255276, "given_name": "C F", "family_name": "Lucchinetti", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.254200Z", "noun_phrases": [ "Myelin oligodendrocyte glycoprotein", "pathologically proven multiple sclerosis", "frequency", "stability", "clinicopathologic correlations" ], "doi": "10.1177/1352458506072189", "access": "open", "takeaways": " Controversy exists regarding the pathogenic or predictive role of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with multiple sclerosis . Four immunopathological patterns (IP) have been recognized in early active MS lesions suggesting heterogeneous pathogenic mechanisms .", "categories": [] }, { "article_id": 439527, "title": "Origin of DSS: to present the plan", "summary": "<jats:p> The Disability Status Scale for multiple sclerosis was the direct result of World War II, in which 16.4 million persons served in the US military. Thereafter academic medicine enabled the modernization of the Veterans Administration in patient care, research, and training. </jats:p><jats:p> Under the GI Bill, I attended Cornell University Medical College, where there was an intensive course in neurological diagnosis requiring detailed recording of positive and negative findings. This was used in junior and senior clinical clerkships and residency training, all of which I took at the Bronx VA Hospital. </jats:p><jats:p> During my residency we assessed a possible treatment for MS, which required a comparison group and a means of measuring change. The former comprised the records of over 300 MS patients, whose neurological deficits were then consolidated into mutually exclusive Functional Systems, each with grades for severity. As rank-order scales they could not be summed or compared directly, but they were used as the basis for the DSS, which ranged from 0 (normal) to 10 (death due to MS). This scale was later expanded into the EDSS by halving each step 1 through 9. This bifid system is applicable to all patients with MS regardless of type or severity of neurological impairment. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506071584", "published_date": "2007-01-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 305509, "given_name": "J F", "family_name": "Kurtzke", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.253224Z", "noun_phrases": [ "Origin", "DSS", "the plan" ], "doi": "10.1177/1352458506071584", "access": "restricted", "takeaways": " The Disability Status Scale for multiple sclerosis was the direct result of World War II . Academic medicine enabled the modernization of the Veterans Administration in patient care, research, and training .", "categories": [] }, { "article_id": 439526, "title": "Familial clustering of multiple sclerosis in a Dutch genetic isolate", "summary": "<jats:p> Multiple sclerosis (MS) is a complex disease with a substantial, yet poorly identified, genetic influence. We estimated the pattern of familial aggregation of MS in a recent genetically isolated population in the Netherlands. Forty-eight MS patients were identified. Their relationship was evaluated by tracing extended pedigrees, making use of municipal and church records. Of the 48 MS patients, 24 could be linked to a common ancestor in 14 generations. However, multiple relationships exist between patients and, to take these into account, we calculated inbreeding and kinship coefficients. We found that MS patients from the isolate were significantly more often related to each other and significantly more often inbred than a non-MS control group, drawn from the same isolate. There was no clustering of Type 1 diabetes and autoimmune thyroid diseases in families of MS patients from this isolate. Finally, HLA typing was performed. Although there was a trend towards a higher prevalence of the HLA DRB1*15 allele in patients compared to controls, differences did not reach significance. This study suggests familial aggregation in the genetically isolated population. The high level of inbreeding makes this population valuable for finding novel genes involved in MS. </jats:p>", "link": "https://journals.sagepub.com/doi/pdf/10.1177/1352458506071216", "published_date": "2007-01-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 270503, "given_name": "I A", "family_name": "Hoppenbrouwers", "ORCID": null, "country": null }, { "author_id": 270504, "given_name": "LM Pardo", "family_name": "Cortes", "ORCID": null, "country": null }, { "author_id": 270505, "given_name": "Y S", "family_name": "Aulchenko", "ORCID": null, "country": null }, { "author_id": 270506, "given_name": "K", "family_name": "Sintnicolaas", "ORCID": null, "country": null }, { "author_id": 270507, "given_name": "O", "family_name": "Njajou", "ORCID": null, "country": null }, { "author_id": 270508, "given_name": "P JLM", "family_name": "Snijders", "ORCID": null, "country": null }, { "author_id": 270509, "given_name": "B A", "family_name": "Oostra", "ORCID": null, "country": null }, { "author_id": 270510, "given_name": "C M", "family_name": "van Duijn", "ORCID": null, "country": null }, { "author_id": 270511, "given_name": "R Q", "family_name": "Hintzen", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-06-09T10:40:10.252324Z", "noun_phrases": [ "Familial clustering", "multiple sclerosis", "a Dutch genetic isolate" ], "doi": "10.1177/1352458506071216", "access": "restricted", "takeaways": " Multiple sclerosis (MS) is a complex disease with a substantial, yet poorly identified, genetic influence . We estimated pattern of familial aggregation of MS in a recent genetically isolated population in the Netherlands . MS patients from the isolate were significantly more often related to each other .", "categories": [] } ] }